Critical Thinking When Reviewing a Randomized Clinical trial

Thach Nguyen MD FACC FSCAI Methodist Hospital, Merrillville IN December 2015



You have 1 minute to evaluate the results of a clinical trial



1. Hard End Points

Total number of

Deaths, Strokes Significant myocardial infarctions






Dual Antiplatelet Therapy Beyond One Year After Drug-eluting Coronary Stent Procedures

Laura Mauri, Dean J. Kereiakes, Robert W. Yeh, Priscilla Driscoll-Shempp, Donald E. Cutlip, P. Gabriel Steg, Sharon-Lise T. Normand, Eugene Braunwald, Stephen D. Wiviott, David J. Cohen, David R. Holmes, Mitchell W. Krucoff, James Hermiller, Harold L. Dauerman, Daniel I. Simon, David E. Kandzari, Kirk N. Garratt, David P. Lee, Thomas K. Pow, Peter Ver Lee, Michael J. Rinaldi, and Joseph M. Massaro on behalf of the Dual Antiplatelet Therapy (DAPT) Study Investigators MACCE

Primary Analysis Period




2. Mechanism of Hard Endpoints

2. Which factor in the hard end points is the driver of the results?



Co-Primary Effectiveness End Points & Components: 12-30 Months



S

3. Risk Profile of the Study Population

Does the risk profile of the patient population match the general patient population in real life?

Morphine's Worrisome Effects on Ticagrelor Affirmed in Pharmacokinetic Study

Variable	Morphine (n = 35)	Placebo (n = 35)	p-value
Female	12 (34%)	7 (20%)	0.19
Body mass index [kg/m²]	27.6 ± 4.3	27.4 ± 4.0	0.87
STEMI	24 (69%)	21 (60%)	0.45
NSTEMI	11 (31%)	14 (40%)	0.45
Metoclopramide use	1 (3%)	0 (0%)	n/a
Hypertension	15 (43%)	21 (60%)	0.15
Diabetes mellitus	8 (23%)	5 (14%)	0.36
Dyslipidemia	30 (86%)	31 (89%)	n/a
Current smoker	17 (55%)	14 (45%)	0.47
Prior AMI	5 (14%)	8 (23%)	0.20
Prior PCI	4 (11%)	9 (26%)	0.12
Prior CABG	0 (0%)	0 (0%)	n/a
Peripheral arterial disease	3 (9%)	1 (3%)	0.31
Chronic renal disease	1 (3%)	2 (6%)	0.31

Table 1. Baseline characteristics of the study patients

AMI — acute myocardial infarction; CABG — coronary artery bypass grafting; n/a — not applicable; NSTEMI — non-ST-segment elevation myocardial infarction; PCI — percutaneous coronary intervention; STEMI — ST-segment elevation myocardial infarction

4. Number of Patients Who Withdraw

5. Impact on Subgroups

1. Diabetes mellitus 2. Coronary artery disease 3. Prior stroke 4. Elderly 5. Young age 6. Women 7. Asian 8. African Americans

Soft End Points



Conclusions

- 1. How was the mortality? (*if YES, then..*)
- 2. Was it mainly from the cardiovascular mortality? *(if YES, then..)*
- 3. How was the risk profile of the studied patient population? (*if YES, then..*)
- 4. Which patients were excluded? (*if YES, then..*)5. Could we translate the results to the general patient population and to other subgroups of patients?

Thank You

